Orkambi
(asked on 8th December 2015) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when he expects Orkambi to be appraised by NICE.
This question was answered on 15th December 2015
The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of Orkambi (lumacaftor in combination with ivacaftor) for the treatment of cystic fibrosis in people who are homozygous for the F508del mutation. NICE’s anticipated publication date for this guidance is July 2016. Further information is available at:
www.nice.org.uk/guidance/indevelopment/gid-tag530